We are live on ! Find out more
CNSP icon

CNS Pharmaceuticals
CNSP

6 hedge funds and large institutions have $425K invested in CNS Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

223% more capital invested

Capital invested by funds: $132K → $425K (+$294K)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

20% more funds holding

Funds holding: 5 → 6 (+1)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
6
Holders Change
+1
Holders Change %
+20%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$209K
2
SAF
Smith Anglin Financial
Texas
+$105K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$52.3K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$24K
2
UBS Group
UBS Group
Switzerland
-$63
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$155K +$209K +4 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$74.1K +$52.3K +1 +100%
SAF
3
Smith Anglin Financial
Texas
$63.5K +$105K +2 New
Geode Capital Management
4
Geode Capital Management
Massachusetts
$30.8K – – –
State Street
5
State Street
Massachusetts
$28.4K – – –
FWA
6
FSM Wealth Advisors
Ohio
$24.2K – – –
VF
7
Virtu Financial
New York
$17K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$14K – – –
XT
9
XTX Topco
Cayman Islands
$12.6K – – –
TRCT
10
Tower Research Capital (TRC)
New York
$5.05K – – –
Fidelity Investments
11
Fidelity Investments
Massachusetts
$267 – – –
Wells Fargo
12
Wells Fargo
California
$263 – – –
Morgan Stanley
13
Morgan Stanley
New York
$170 – – –
GRP
14
Global Retirement Partners
California
$38 – – –
Bank of America
15
Bank of America
North Carolina
$1 – – –
PMFA
16
Plante Moran Financial Advisors
Michigan
$1 – – –
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
– -$24K -1 Closed
UBS Group
18
UBS Group
Switzerland
– -$63 – –

CNSP Hedge Fund Activity: Q4 2023 in Review

6 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q4 2023, worth a combined $425K — up 223% from $132K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new CNSP positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $209K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $24K sold.

  • 6 institutional investors held CNS Pharmaceuticals (CNSP) as of Q4 2023, up from 5 in Q3 2023.
  • Funds reported $425K of CNS Pharmaceuticals stock for Q4 2023, up 223% quarter-over-quarter.
  • 2 funds opened new CNS Pharmaceuticals positions in Q4 2023 and 1 closed out, a net change of +1 holder.
  • The largest CNS Pharmaceuticals buyer in Q4 2023 was Armistice Capital, an estimated $209K added.
  • The largest CNS Pharmaceuticals seller in Q4 2023 was Susquehanna International Group, an estimated $24K sold.

Based on aggregated 13F filings for Q4 2023.